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Background. End-stage renal disease (ESRD) patients under hemodialysis (HD) have high mortality rate. Inflammation, dyslipi-
demia, disturbances in erythropoiesis, iron metabolism, endothelial function, and nutritional status have been reported in these
patients. Our aim was to identify any significant association of death with these disturbances, by performing a two-year follow-up
study. Methods and Results. A large set of data was obtained from 189 HD patients (55.0% male; 66.4 ± 13.9 years old), including
hematological data, lipid profile, iron metabolism, nutritional, inflammatory, and endothelial (dys)function markers, and dialysis
adequacy. Results. 35 patients (18.5%) died along the follow-up period. Our data showed that the type of vascular access, C-reactive
protein (CRP), and triglycerides (TG) are significant predictors of death. The risk of death was higher in patients using central
venous catheter (CVC) (Hazard ratio [HR] =3.03, 95% CI = 1.49–6.13), with higher CRP levels (fourth quartile), compared with
those with lower levels (first quartile) (HR = 17.3, 95% CI = 2.40–124.9). Patients with higher TG levels (fourth quartile) presented
a lower risk of death, compared with those with the lower TG levels (first quartile) (HR = 0.18, 95% CI = 0.05–0.58). Conclusions.
The use of CVC, high CRP, and low TG values seem to be independent risk factors for mortality in HD patients.
1. Introduction
Patients with end-stage renal disease (ESRD) have a high
mortality rate [1, 2] that far exceeds the mortality rate for
the non-ESRD population [3]. In the past half-century, the
widespread use of hemodialysis (HD) to prolong life of ESRD
patients has been a remarkable achievement, preventing
death from uremia in these patients. Nowadays this therapy
has expanded widely and is being used by an increasing
elderly patient population, leading to significant economic
consequences to patients and to healthcare systems.
Our present knowledge of the mechanisms leading to
increased death in this context is incomplete. In the last years,
this medical field has known significant technological and
pharmacological improvements. Although some evidence
may suggest that mortality rate among dialysis patients has
decreased over the last few years, actually, patient’s survival is
still low. Cardiovascular disease (CVD) has been considered
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the most common cause of death in these patients [4].
Cardiac arrest and congestive heart failure are more promi-
nent causes of cardiovascular death than acute myocardial
infarction in patients with uremia. A higher mortality rate
within the first year after initiation of HD has been described
(the period of highest risk for death extends to approximately
120 days after starting dialysis).
The high risk of cardiovascular morbidity and mor-
tality in ESRD patients is associated with a high preva-
lence of classic cardiovascular risk factors (hypertension,
diabetes mellitus, dyslipidemia, smoking, and advanced
age). In addition, several uremia-related factors may also
play an important role, namely, the presence of multi-
ple comorbid conditions, fluid overload, hyperphospho-
remia, high calcium-phosphorous product, anemia, left ven-
tricular hypertrophy, inflammation, oxidative stress, endo-
thelial dysfunction, insulin resistance, excess sympathetic
tone, hyper-homocysteinemia, high levels of lipoprotein(a),
and increased asymmetrical dimethylarginine [5–8]. Recent
reports have highlighted the importance of noncardiovascu-
lar mortality in HD patients and that it has been underesti-
mated [3].
Systemic inflammation is frequently present in ESRD
patients, and the use of central venous catheter (CVC) has
been associated with an enhanced inflammatory state [9].
The aim of the present study was to evaluate the global
mortality in Portuguese ESRD patients under HD, by per-
forming a follow-up study of two years, in order to identify
any significant association of death with systemic parameters,
including dialysis adequacy, nutritional status, hematological
data, lipid profile, iron metabolism, and inflammatory and
endothelial (dys)function markers, as well as the type of vas-
cular access, presence of comorbidities, and with associated
therapies. The parameters associated with mortality in this
context may provide biomarkers to be used in the clinical
setting.
2. Methods
2.1. Patients. This research protocol was approved by the
Ethics Committee of Fresenius Medical Care, Portugal. All
participants gave their written informed consent to partici-
pate in this study.
In this two-year follow-up study, starting fromApril 2009,
189 HD patients, from 3 dialysis clinics in the Northern
region of Portugal, were included in the study.These patients
were under HD for at least 90 days. At the start of the
study, the patients were clinically evaluated and blood was
collected for the analytical studies; afterwards, a clinical
followupwas performed during two years, in order to identify
the cases of death, transplant, and transfer to peritoneal
dialysis. Data regarding demographic characteristics, chronic
kidney disease and medical history, dialysis, and medical
prescriptions, as well as laboratory data, was also collected at
the start of the study.
Diabetes was defined by the current guidelines [10]
or by the use of insulin or oral hypoglycemic agents.
Hypertension was defined by the current guidelines (blood
pressure > 130/85mm Hg) [11] or by the use of antihy-
pertensive medication. Therapy with recombinant human
erythropoietin (rhEPO) and with intravenous iron was based
on the current guidelines.The classification of ESRD patients
as responders or nonresponders to rhEPO therapy was
performed in accordance with the European Best Practice
Guidelines [12]. Patients with autoimmune disease, malig-
nancy, and acute or chronic infection were excluded.
A group of 25 healthy volunteers was selected as control,
based on normal hematological and biochemical values, and
no history of kidney or inflammatory diseases, in order to
better define the changes occurring in HD patients. This
groupwasmatched, as far as possible, for age and gender with
HD patients.
2.2. Assays. Blood sampleswere obtained immediately before
theHDprocedure, in themidweek dialysis day, andprocessed
within 2 hours after collection. Blood was collected to tubes
with (EDTA) and without anticoagulant, in order to obtain
whole blood, plasma, buffy-coat, and serum. Aliquots were
immediately stored at −80∘C, whenever necessary, until
assayed.
Erythrocyte count, hematocrit, hemoglobin concentra-
tion, and hematimetric indices (mean cell volume (MCV),
mean cell hemoglobin (MCH), and mean cell hemoglobin
concentration (MCHC)) were measured by using an auto-
matic blood cell counter (Sysmex K1000; Sysmex, Hamburg,
Germany). Leukocyte differential counts were evaluated in
Wright-stained blood films. Reticulocyte count was made by
microscopic counting on blood smears after vital staining
with newmethylene blue (reticulocyte stain; Sigma, St. Louis,
MO, USA). The reticulocyte production index (RPI) was
calculated, as an appropriate way to measure the effective
erythrocyte production, by correcting for both changes in
hematocrit (degree of anemia) and for premature reticulocyte
release from the bone marrow.
Serum albumin levels were measured using a col-
orimetric assay end-point method (Albumin Plus; Roche
GmbH, Mannheim, Germany). Serum iron concentration
was determined using a colorimetric method (Iron, Randox
Laboratories Ltd., North Ireland, UK), whereas serum fer-
ritin and serum transferrin were measured by immunotur-
bidimetry (Ferritin, Laboratories Ltd., North Ireland, UK;
Transferrin, Laboratories Ltd., North Ireland, UK). Enzyme-
linked immunosorbent assays were used for measurement
of plasma soluble transferrin receptors (s-TfR) (Human
sTfR immunoassay, R&D systems, MN, USA); transferrin
saturation (TS) was calculated by the formula: TS (%) =
70.9 × serum iron concentration (mg/dL)/serum transferrin
concentration (mg/dL).
Plasma concentration of adiponectin, interleukin (IL)-
6, tissue plasminogen activator (tPA), and plasminogen
activator inhibitor-1 (PAI-1) were evaluated by using standard
commercial enzyme-linked immunoassays (adiponectin, IL-
6 ELISA High-Sensitivity, tPA, and PAI-1, all from eBio-
science). D-dimer and C-reactive protein (CRP) were eval-
uated by immunoturbidimetry, using commercially available
kits (BCS XP system, Siemens, Germany; CRP (latex) High-
Sensitivity, Roche Diagnostics, resp.).
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The activity of paraoxonase 1 (PON1) was assessed spec-
trophotometrically and expressed in nmol of p-nitrofenol/
mL/min. Briefly, PON1 activity was measured by adding
serum to 1mL Tris/HCl buffer (100mmol/L, pH 8.0) contain-
ing 2mmol/L CaCl
2
and 5.5mmol/L paraoxon (O,O-diethyl-
O-p-nitrophenylphosphate, SigmaChemical Co.).The rate of
generation of p-nitrophenol was determined by reading the
absorbance at 412 nm, 37∘C, with the use of a continuously
recording spectrophotometer (Beckman DU-68).
The evaluation of serum hepcidin concentration was
performed by using an enzymatic immunoassay (Hepcidin-
25, EIAKit Extraction-Free, Peninsula Laboratories, LLC, San
Carlos, CA, USA).
Serum lipids, lipoproteins, and apolipoprotein analysis
were performed in an autoanalyser (Cobas Mira S, Roche,
Basel, Switzerland) using commercially available kits.
Serum total cholesterol and triglycerides concentrations
were performed by enzymatic colorimetric tests (cholesterol
oxidase-phenol aminophenazone and glycerol-3-phospate
oxidase-phenol aminophenazone methods, Roche, resp.).
High-density lipoprotein cholesterol (HDLc) and low-
density lipoprotein cholesterol (LDLc) levels were measured
using enzymatic colorimetric tests, after selective separation
of HDL and LDL fractions (Direct HDLCholesterol
and Direct LDLCholesterol, Roche). Serum levels of
apolipoprotein (Apo) A-I and Apo B were evaluated by
immunoturbidimetric assays (uni-kit apolipoproteinA-I and
B specific antiserums, Roche). Serum Lp(a) was quantified
by using an immunoturbidimetric method (Lp(a), Roche
Diagnostics). Oxidized LDL (ox-LDL) was measured directly
in plasma by using a two-site enzyme immunoassay (oxidized
LDL ELISA, Mercodia, Uppsala, Sweden).
2.3. Statistical Analysis. Kolmogorov-Smirnov test was used
to test for normality of the variable distributions. Patients
were categorized according to their status at the end of
the 2 years of followup: alive (group 1) or dead (group 2).
Differences between groups were analyzed by using Student’s
𝑡-test orMann-Whitney test, according to the results obtained
in the Kolmogorov-Smirnov test. Normally distributed vari-
ables are presented as mean ± SD and those nonnormally
distributed are presented as median (interquartile range).
Proportionswere compared between groups using chi-square
tests.
Survival analysis taking competing risks into account
was performed to analyze patient’s survival. The event of
interest was death and the competing risk event was renal
transplantation. Patients transferred to peritoneal dialysis
were excluded (given the small number involved (𝑛 = 2)).
Estimates of cumulative incidence function were calculated.
Regressionmodels taking competing risks into account (Fine
and Gray model based on subdistribution hazard model)
were carried out, to analyze the effect of covariates in patient’s
survival. To decide which variables should be included in
the final multivariable model, an exploratory analysis was
performed by fitting models for each variable in turn, adjust-
ing for age and previous time in HD. The final multivariable
model included all of these candidate variables with 𝑃 values
<0.05. All analyses were performed with SPSS and R software
using the packages cmprsk, and significance level (𝛼) was set
at 0.05.
3. Results
3.1. Patient’s Demographic and Clinical Data. We studied
189 ESRD patients under HD (104 male, 85 female; mean
age: 66.4 years, SD 13.9 years, range 27.6–92.0 years). The
patients were under therapeutic HD three times per week,
for 3–5 hours, and were under HD for 2.13 (0.82–5.28) years,
when they were included in this study. All patients used
the high-flux polysulfone FX-class dialyzers (1.4–2.2m2) of
Fresenius (Bad Hamburg, Germany). Arteriovenous fistula
(AVF) was used by 146 patients (77.2%), whereas 43 patients
(22.8%) had a CVC. The main causes of renal failure in
these patients were diabetes mellitus (𝑛 = 68), followed by
arterial hypertension (𝑛 = 25), glomerulonephritis (𝑛 = 16),
polycystic renal disease (𝑛 = 12), reflux nephropathy (𝑛 =
8), obstructive uropathy (𝑛 = 4), hereditary nephropathy
(𝑛 = 3), chronic interstitial nephritis (𝑛 = 2), nephrolithiasis
(𝑛 = 3), other diseases (𝑛 = 7), and uncertain etiology
(𝑛 = 40). Sixteen (8.5%) patients were classified as resistant
to rhEPO therapy. A total number of 108 patients (63.9%)
had arterial hypertension, 103 patients (54.5%) were under
antihypertensive treatment, 75 (39.7%) were using statins, 127
(67.2%) were under intravenous iron therapy, 71 (39.0%) were
under anti platelet therapy, and 8 (4.6%) were under oral
hypocoagulation.
3.2. Analytical Data. The analytical results for the patients
at starting of the follow-up study, and for the control group,
are presented in Table 1. The hematological study showed
that the HD patients experience a significant decrease in
hemoglobin concentration, hematocrit, erythrocyte, platelets
and lymphocyte counts, and a significant increase inMCV, as
compared with the control; several significant changes were
also observed in iron metabolism (an increase in transferrin
saturation, sTfR, ferritin and hepcidin, and a decrease in
iron and transferrin), in inflammatory markers (increase in
adiponectin, IL-6, and CRP and a decrease in PON1), in the
lipid profile (increase in oxLDL/LDL ratio and a decrease
in total cholesterol, HDLc, LDLc, Apo A, Apo B and ox-
LDL), in endothelial (dys)function markers (an increase in
tPA, tPA/PAI-1 ratio and D-dimers, and a decrease in PAI-1);
a significant increase in BMI, was also observed in patients,
when compared with the control group.
3.3. Outcome. During the follow-up period (24 months),
35 patients died (18.5%) and 18 patients received a kidney
transplant. Table 2 shows the values of the parameters that
presented significant differences, when considering dead and
alive patients at the end of the 2-year follow-up period.
Statistically significant differences were found, concerning
dialysis markers, nutritional status, hematological data, iron
metabolism, inflammation, lipid profile, and endothelial
function. The patients that died during the study period
showed significantly lower values for calcium, calcium phos-
phorus product, creatinine, ultrafiltration volume, transfer-
rin, transferrin saturation, triglycerides, VLDL, Apo A, BMI,
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Table 1: Baseline values of the 189 ESRD patients under HD therapy.
Controls (𝑛 = 25) HD patients (𝑛 = 189)
Biochemical and dialysis markers
URR, % — 75.9 ± 6.56
KT/Ve — 1.48 ± 0.31
Ultrafiltration volume, L — 2.43 ± 0.94
Creatinine, mg/dL — 8.14 ± 2.81
Potassium, mmol/L — 5.40 (4.80–5.88)
Sodium, mmol/L — 137 (135–139)
Phosphorus, mmol/L — 4.48 (3.60–5.40)
Calcium, mg/dL — 8.60 (8.10–9.10)
Calcium phosphorus product — 37.58 (31.15–44.86)
Darbopoeitin, 𝜇g/kg/week — 0.42 (0.20–0.75)
Hematological data
Erythrocytes, ×1012 /L 4.9 ± 0.45 3.8 ± 0.53∗
Hemoglobin, g/dL 14.9 ± 0.86 11.7 ± 1.44∗
Hematocrit, % 44.3 ± 2.80 36.5 ± 4.59∗
MCV, fL 88.1 ± 11.72 95.8 ± 6.01∗
MCHC, g/dL 33.8 ± 0.46 32.3 ± 1.19
RDW, % 15.1 ± 0.54 15.1 ± 1.91
Platelets, ×109/L 257.1 ± 58.85 184.1 ± 55.4∗
Leukocytes, ×109/L 6.7 ± 1.66 6.4 ± 2.0
Neutrophils, ×109/L 4.3 ± 1.48 4.0 ± 1.49
Lymphocytes, ×109/L 2.0 ± 0.37 1.7 ± 0.70∗
Neutrophil/lymphocyte ratio 2.2 ± 0.78 2.7 ± 1.51
Iron metabolism markers
Transferrin, mg/dL 310.8 ± 44.04 184.4 ± 35.8∗
Transferrin saturation, % 12.7 ± 4.73 15.1 (11.8–19.3)∗
Iron, 𝜇g/dL 55.0 ± 17.97 38.0 (30.0–53.5)∗
sTfR, nmol/L 13.6 ± 3.72 23.3 ± 11.9∗
Ferritin, ng/mL 102.5 ± 60.61 400.8 ± 152.9∗
Hepcidin-25, ng/mL 218.4 (124.5–318.6) 1599.1 (863.6–2409.0)∗
Inflammatory markers
IL-6, pg/mL 0.43 (0.28–0.61) 2.29 (1.40–4.26)∗
CRP, mg/dL 0.75 (0.44–1.91) 5.13 (2.33–13.05)∗
PON1, nmol p-nitrofenol/mL/min 466.8 (383.8–535.8) 361.1 (323.3–463.7)∗
Adiponectin, mg/L 4.93 ± 2.30 9.27 ± 4.71∗
Lipid profile
Total cholesterol, mg/dL 202.2 ± 26.25 154.2 ± 43.5∗
Triglycerides, mg/dL 103.0 (86.5–154.0) 117.0 (90.5–176.5)
HDLc, mg/dL 48.7 ± 12.94 42.2 ± 13.5∗
LDLc, mg/dL 105.9 ± 25.29 73.4 ± 29.3∗
VLDL, mg/dL 20.6 (17.3–30.8) 23.4 (18.0–35.4)
Lp(a), mg/dL 27.7 (17.3–69.9) 45.4 (25.6–89.0)
Apo A1, mg/dL 145.2 ± 26.91 122.7 ± 30.4∗
Apo B, mg/dL 91.4 ± 14.49 72.4 ± 21.7∗
Ox-LDL, U/L 40.8 ± 10.97 33.7 (27.7–40.5)∗
OxLDL/LDL ratio, U/mg 0.040 ± 0.013 0.052 ± 0.018∗
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Table 1: Continued.
Controls (𝑛 = 25) HD patients (𝑛 = 189)
Endotelial (dys) function markers
tPA, ng/mL 3.93 (2.95–5.93) 5.35 (3.72–8.18)∗
PAI-1, ng/mL 31.0 (15.3–59.2) 18.7 (12.1–32.4)∗
tPA/PAI-1 ratio 0.16 (0.09–0.20) 0.29 (0.18–0.39)∗
D-dimers, ng/mL 0.25 (0.18–0.34) 0.71 (0.38–1.56)∗
Nutritional markers
BMI, Kg/m2 22.2 ± 2.26 25.9 ± 4.63∗
Albumin, g/dL — 3.9 ± 0.38
∗
𝑃 < 0.05 versus controls. Data are presented as median and interquartile range (parameters with nonnormal distribution), mean and standard deviation
(parameters with normal distribution), or number and respective percentage. URR: urea reduction ratio; MCV: mean cell volume; MCHC: mean cell
hemoglobin concentration; RDW: red cell distribution width; sTfR: soluble transferrin receptor; IL-6: interleukin-6; CRP: C-reactive protein; PON 1:
paraoxonase 1; HDLc: high-density lipoprotein cholesterol; LDLc: low-density lipoprotein cholesterol; VLDL: very low-density lipoprotein; Lp(a): lipoprotein
(a); Apo A: apolipoprotein A; Apo B: apolipoprotein B; Ox-LDL: oxidized LDL; PAI-1: plasminogen activator inhibitor-1; tPA: tissue plasminogen activator.
Table 2: Baseline values in ESRD patients under HD therapy for variables in which significant differences were found when the patients were
divided in two groups (alive or dead 2 years later).
Alive at followup (135 patients) Dead during followup (35 patients) P
Biochemical and dialysis markers
Calcium, mg/dL 8.70 (8.20–9.10) 8.40 (8.00–8.90) 0.046
Calcium phosphorus product 38.6 (31.4–46.5) 35.8 (29.2–39.2) 0.025
Creatinine, mg/dL 8.63 ± 2.86 6.45 ± 2.10 <0.001
Ultrafiltration volume, L 2.47 ± 0.85 2.29 ± 1.22 0.037
Darbopoeitin-𝛼, 𝜇g/kg/week 0.40 (0.77–0.66) 0.87 (0.36–1.47) <0.001
Hematological data
RDW, % 14.5 ± 1.43 16.9 ± 2.32 <0.001
Iron metabolism markers
Transferrin, mg/dL 187.6 ± 34.1 172.5 ± 41.6 0.050
Transferrin saturation, % 15.8 (12.3–19.7) 13.5 (9.67–19.1) 0.032
Inflammatory markers
IL-6, pg/mL 2.21 (1.37–3.60) 4.27 (2.10–6.57) <0.001
CRP, mg/dL 3.93 (2.09–9.73) 14.9 (5.15–30.4) <0.001
Lipid profile
Triglyceride, mg/dL 120.0 (95.0–180.0) 103.0 (82.0–125.0) 0.015
VLDL, mg/dL 24.0 (18.8–36.0) 20.6 (16.4–25.0) 0.021
Apo A1, mg/dL 124.3 ± 29.7 109.4 ± 26.2 0.014
Endotelial (dys) function markers
PAI-1, ng/mL 17.9 (12.3–30.4) 27.4 (14.2–46.9) 0.034
D-dimers, ng/mL 0.70 (0.40–1.29) 1.47 (0.63–2.28) 0.005
Nutritional markers
Body mass index, kg/m2 25.4 (23.0–28.5) 23.3 (20.5–27.3) 0.008
Albumin, g/dL 4.00 (3.78–4.20) 3.70 (3.37–3.94) <0.001
Data are presented as means and standard deviation or median (interquartile range). RDW: red blood cells distribution width; IL-6: interleukin-6; CRP: C-
reactive protein; VLDL: very low-density lipoprotein; Apo A: apolipoprotein A; PAI-1: plasminogen activator inhibitor 1.
and albumin; significantly higher values were found for
RDW, IL-6, CRP, PAI-1, and tPA. Moreover, dead patients
required significantly higher rhEPO doses to achieve the
target hemoglobin levels and presented a significantly higher
percentage of patients using CVC (38% versus 15%, 𝑃 <
0.001) as the vascular access for the HD procedure.
Figure 1 summarizes the cumulative incidence curves
estimating all possible outcomes, taking competing risks into
account. The probability of death by 6, 12, 18, and 24 months
after starting the study was 0.053, 0.106, 0.154, and 0.176,
respectively.
Survival regression models, all adjusted for age and
previous time in HD, are presented in Table 3. This analysis
showed that the type of vascular access (the use of CVC),
CRP, and tryglicerides are significant predictors of the event
of interest, death. Indeed, the risk of death was higher for
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Table 3: Survival regression models for ESRD patient’s mortality.
Model 1∗ Final model∗∗
Adjusted hazard ratio 95% CI P Adjusted hazard ratio 95% CI P
Type of vascular access
CVC versus AVF 2.65 1.33–5.30 0.006 3.03 1.49–6.13 0.002
C-reactive protein
Q2 versus Q1 6.01 0.79–46.7 0.083 4.91 0.62–38.6 0.130
Q3 versus Q1 8.04 1.04–62.2 0.046 8.31 1.09–63.1 0.041
Q4 versus Q1 18.1 2.51–130.0 0.004 17.3 2.40–124.9 0.005
Triglycerides
Q2 versus Q1 0.46 0.20–1.02 0.057 0.48 0.19–1.21 0.120
Q3 versus Q1 0.48 0.20–1.13 0.093 0.48 0.17–1.34 0.160
Q4 versus Q1 0.22 0.07–0.75 0.015 0.18 0.05–0.58 0.004
∗Model 1: hazard ratio adjusted for age and previous time on HD; ∗∗Final model: hazard ratio adjusted for all variable in the model. CVC: central venous
catheter; AVF: arteriovenous fistula; Q: quartile; CI: confidence interval.












Figure 1: Cumulative incidence curves for all possible events (death
as event of interest and transplantation as competing risk) for ESRD
patients.
CVC (hazard ratio (HR) = 3.03, 95% CI = 1.49–6.13) and for
patients with higher levels of CRP (4th quartile), as compared
with the patientswith lower level (1st quartile) (HR= 17.3, 95%
CI = 2.40–124.9) (Table 3). Patients with tryglicerides levels in
the 4th quartile had a lower risk of death, as compared with
those patients in the 1st quartile (HR = 0.18, 95% CI = 0.05–
0.58).
4. Discussion
In the present study, 189 ESRD patients under HD therapy
were studied at the start of the study and followed for 2 years,
in order to identify parameters that could be associated with
mortality and, therefore, to provide biomarkers of risk.
The mortality rate in HD remains high [3, 13], in spite
of the considerable improvements in medical and technical
support to these patients in the last years. CVD events are
the main causes of mortality in ESRD patients [4]. However,
it has been argued that noncardiovascular causes of death
seem to be increasing to the same extent as cardiovascular
mortality in ESRD patients [3]. Shastri et al. studied the
patterns of death in a large cohort of HD patients and showed
that sudden cardiac death accounted for 22% of the fatal
events, whereas nonsudden cardiac death and noncardiac
death accounted for 17% and 61%, respectively [14].
In our study, during the follow-up period, 35 patients
died (18.5%) and 18 patients received a kidney transplant.
Considering dead and living patients at the end of the 2-
year follow-up period, we found that several variables were
significantly different for the two groups of patients. We
found that the patients who died during the follow period
of the study, as compared to living patients, had lower HD
efficacy, as showed by lower values of calcium, calcium
phosphorus product, creatinine, and ultrafiltration volume;
higher disturbances in iron metabolism and erythropoiesis,
as shown by lower values of transferrin and transferrin satu-
ration and higher values of RDW; a poor nutritional status,
as reflected by the lower values of triglycerides, VLDL, Apo
A, BMI, and albumin; a higher inflammatory condition, as
shown by the higher values of IL-6 and CRP; endothelial and
hemostatic disturbances, as suggested by the higher values
of PAI-1 and D-dimers; and the development of resistance
to rhEPO therapy, as they needed higher rhEPO doses to
achieve hemoglobin concentrations within the target range;
a higher percentage of them used CVC for vascular access.
After performing amultivariate analysis, we observed that the
use of CVC as the vascular access for the HD procedure, high
CRP levels, and low triglycerides levels were independently
associated with mortality.
The present work, showing an association between mor-
tality in ESRDpatients underHD treatment and both the type
of vascular access (CVC) and CRP, shows that inflammation
plays an important role in the mortality of these patients
[15] and that their values can be used as predictors of
death. Whether inflammation has any significant role in the
physiopathology of ESRD, leading to death, or is merely a
risk marker remains to be established. Zimmermann et al.,
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studying 280 HD patients, showed CRP as an independent
predictor of both overall death and cardiovascular death [15],
which is in agreement with our findings.
In a previous report [9], we showed that ESRD patients
with a CVC had lower levels of hemoglobin and albumin
and higher levels of CRP, IL-6, D-dimers, and tPA, when
compared to ESRD patients using AVF [5]. This association
between CVC use and the enhancement of the inflammatory
process and endothelial dysfunction could justify the high
mortality rate found in ESRD patients using CVC. Several
other reports [16, 17] have shown an association between the
type of vascular access and mortality in HD patients.
Low values for plasma triglycerides were also associated
with mortality in this study. This finding must be seen in
the context of a significant importance of malnutrition in
this type of patients [18]. Owen et al. showed serum albumin
concentration as a powerful predictor of death in a cohort
of 13, 473 HD patients [18]. In our study, albumin presented
lower values in patients that died during followup; however,
the survival regression models did not show albumin as
an independent risk factor. The low levels of triglycerides
might reflect a “malnutrition-inflammation complex syn-
drome” [19] or,more probably, a hemodialysis-catabolic state,
associated with increased mortality.
Most of the changes (Table 1) observed in the char-
acterization of HD patients are in accordance with the
literature. HD patients presented with anemia, as shown
by a decreased hemoglobin concentration, hematocrit, and
erythrocyte count. They also presented a decrease in platelet
and lymphocyte counts. The lymphocytopenia seems to
result, at least in part, from a decrease in total circulating
CD3+ T-lymphocytes and affects both the CD4+ and the
CD8+ T-cell subsets [20]. The presence of inflammatory
features (increased levels of IL-6 and CRP and decreased
PON1 activity) were consistent with findings reported in HD
patients [21–23]; however, the causes for the inflammatory
response are not well clarified. Indeed, there are several
potential sources, including bacterial contamination of the
dialyser, incompatibility with the dialyser membrane, and
the vascular access. It is known that some inflammatory
players, for example, hepcidin, have an important impact in
iron metabolism, reducing the mobilization and absorption
of iron for erythropoiesis [24], leading, therefore, to an iron
depleted erythropoiesis. In accordance with this, we found
an increase in sTfR, ferritin, and transferrin saturation and
a decrease in transferrin and in iron serum levels. IL-6,
which is significantly increased in HD patients (Table 1), is
known to strongly induce hepcidin mRNA expression [25,
26].Thus, the high levels of hepcidin found in HD patient are
explained by the underlying chronic inflammation. Recent
studies have reported that higher body mass index (BMI)
plays a protective role in HD patients [27–29]. Actually, the
increased BMI in our HD patients was associated with higher
adiponectin serum levels. Adiponectin is an adipokine that
exerts a variety of anti-inflammatory activities, interfering
with macrophage function by inhibiting phagocytosis, the
production of IL-6 and TNF𝛼, T-cell function, and by
promoting the release of IL-10 and IL-1 receptor antagonists
[30, 31].The increase in adiponectin suggests that the adipose
tissue in HD patients may influence or modulate the inflam-
matory response. Several changes in the lipid profile were also
found, namely, a decrease in total cholesterol, HDLc, LDLc,
ApoA, ApoB, and Ox-LDL. In spite of the decrease in Ox-
LDL, a higher ox-LDL/LDL ratiowas found, showing a higher
proportion of oxidized LDL particles in HD patients. It is
known that ox-LDLs present important proinflammatory and
procoagulant properties [32], and, therefore, it may further
contribute to inflammatory changes. Endothelial function
was also disturbed, as shown by the increase in D-dimers
and tPA/PAI-1 ratio. It is uncertain if the higher values of
fibrin fragment D-dimers in HD patients result from a higher
activation of coagulation and/or of fibrinolysis, though the
higher tPA values and tPA/PAI-1 ratio suggest an increase in
fibrinolysis and a disturbance in endothelial function.
This study presented some limitations, namely, the num-
ber of patients included in this study and the follow-up period
that were relatively limited.
In conclusion, our study showed that the type of vascular
access for HD procedure, inflammation, and the nutritional
status of the patients are important factors for the survival of
these patients and that the use of CVC, CRP, and TG values
may provide good biomarkers of risk in ESRD patients under
HD.
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